Roche Strengthens Hematology Pipeline Through Nurix Therapeutics Partnership
Roche announced that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialise bexobrutideg (NX-5948), Nurix’s investigational Bruton’s Tyrosine Kinase (BTK) degrader. The…
